KLRC1 and nasopharyngeal carcinoma: With regards to NK cell phenotypes, one study noted no difference in terms of percentage of NK cells positive for NKG2D (NK activating) and KIR2DL2/DL3 (CD158b) and NK2GA (CD159a) (both NK inhibitory) between NPC and healthy controls [122].